Real-life use of edoxaban (Lixiana®, Daiichi Sankyo) in Asian atrial fibrillation (AF) patients significantly lowered the risk of ischaemic stroke (IS), intracranial haemorrhage (ICH), hospitalisation for gastrointestinal (GI) bleeding, hospitalisation for major bleeding, and all-cause death when compared to warfarin. This was concluded by the Korean investigators in the Journal of the American College of Cardiology. The benefits were consistent in the various high-risk subgroups.
https://medi-paper.com/wp-content/uploads/2018/08/cv2.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png News Feed2018-08-29 23:13:062018-08-29 23:13:06Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety
MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | MediNews.asia | Anaesthesiology.asia